Interferon beta-1b Alternatives Compared
| Interferon beta-1b | Kesimpta (ofatumumab) | Zeposia (ozanimod) |
|
|---|
| Interferon beta-1b | Kesimpta (ofatumumab) | Zeposia (ozanimod) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Colorectal Cancer. Interferon beta-1b may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Multiple Sclerosis. Kesimpta may also be used for purposes not listed in this medication guide. |
Prescription only
Zeposia is an S1P receptor modulator that may be used to treat relapsing forms of multiple sclerosis or ulcerative colitis in adults. It requires a 7-day titration period and reduces lymphocyte... View more |
||||||||
| More about Interferon beta-1b | More about Kesimpta (ofatumumab) | More about Zeposia (ozanimod) | ||||||||
| Ratings & Reviews | ||||||||||
|
Interferon beta-1b has an average rating of 7.1 out of 10 from a total of 9 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 11% reported a negative effect. |
Kesimpta has an average rating of 6.9 out of 10 from a total of 71 ratings on Drugs.com. 51% of reviewers reported a positive effect, while 18% reported a negative effect. |
Zeposia has an average rating of 8.3 out of 10 from a total of 7 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Kesimpta prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms Available | ||||||||||
|
N/A |
|
|
||||||||
| Brand Names | ||||||||||
| Betaseron, Extavia | Other ofatumumab brands include: Arzerra |
N/A |
||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
4.3 hours |
1476 hours |
264 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 337 drugs are known to interact with Interferon beta-1b:
|
A total of 172 drugs are known to interact with Kesimpta:
|
A total of 904 drugs are known to interact with Zeposia:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
N/A |
N/A |
March 25, 2020 |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
| Professional Resources | ||||||||||
|
N/A |
||||||||||
| Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.